Literature DB >> 14688560

Growth, survival and viral load in symptomatic childhood human immunodeficiency virus infection.

Caroline J Chantry1, Robert S Byrd, Janet A Englund, Carol J Baker, Ross E McKinney.   

Abstract

BACKGROUND: The relationships among weight and height growth, viral load and survival in HIV-infected children remain unclear.
OBJECTIVES: To determine whether weight or height growth velocity independently predicts survival and to investigate associations of weight, height and head circumference growth velocities with viral loads in symptomatic HIV-infected children.
METHODS: We analyzed data from a prospective antiretroviral study utilizing clinical endpoints (PACTG 152). Viral load [log(RNA PCR)] and anthropometric measures 12 weeks before and after viral load measures were available in 494 of 831 children. Interval changes during 24 weeks in z-scores for weight-for-age (DeltaWAZ), height-for-age (DeltaHAZ) and head circumference-for-age (DeltaHCZ) were used as growth velocity surrogates. Logistic regression determined whether DeltaWAZ and/or DeltaHAZ correlated with survival when age, viral load and CD4+ cell count were controlled. Bivariate analysis assessed correlation among viral load and DeltaWAZ, DeltaHAZ and/or DeltaHCZ.
RESULTS: Survival related significantly to height growth velocity (P = 0.03, n = 434) but not to weight growth velocity (P = 0.84, n = 446) or head circumference growth velocity (P = 0.67, n = 148). Viral load was not significantly associated with changes in weight-, height-, or head circumference-for-age z scores (P = 0.86, n = 235; P = 0.07, n = 226; and P = 0.09, n = 165, respectively) in children <30 months of age or with changes in weight- or height-for-age z scores (P = 0.27, n = 259; P = 0.11, n = 251) in older children.
CONCLUSIONS: Height growth velocity predicted survival independently of age, viral load and CD4+ cell count. Weight, height and head circumference growth velocities were not significantly associated with viral load in symptomatic HIV-infected children in this large prospective trial of nucleoside reverse transcriptase therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14688560     DOI: 10.1097/01.inf.0000100575.64298.bc

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  14 in total

Review 1.  Perinatally infected adolescents living with human immunodeficiency virus (perinatally human immunodeficiency virus).

Authors:  Maria Leticia S Cruz; Claudete A Cardoso
Journal:  World J Virol       Date:  2015-08-12

2.  Predictors of growth and body composition in HIV-infected children beginning or changing antiretroviral therapy.

Authors:  C J Chantry; J S Cervia; M D Hughes; C Alvero; J Hodge; P Borum; J Moye
Journal:  HIV Med       Date:  2010-03-21       Impact factor: 3.180

Review 3.  Impact of antiretroviral therapy on growth, body composition and metabolism in pediatric HIV patients.

Authors:  Roy J Kim; Richard M Rutstein
Journal:  Paediatr Drugs       Date:  2010-06       Impact factor: 3.022

4.  Younger age at HAART initiation is associated with more rapid growth reconstitution.

Authors:  Christine J McGrath; Michael H Chung; Barbra A Richardson; Sarah Benki-Nugent; Danson Warui; Grace C John-Stewart
Journal:  AIDS       Date:  2011-01-28       Impact factor: 4.177

5.  Associations of proinflammatory cytokine levels with lipid profiles, growth, and body composition in HIV-infected children initiating or changing antiretroviral therapy.

Authors:  Joseph S Cervia; Caroline J Chantry; Michael D Hughes; Carmelita Alvero; William A Meyer; Janice Hodge; Peggy Borum; Jack Moye; Stephen A Spector
Journal:  Pediatr Infect Dis J       Date:  2010-12       Impact factor: 2.129

6.  Anti-retroviral therapy reduces incident tuberculosis in HIV-infected children.

Authors:  Andrew Edmonds; Jean Lusiama; Sonia Napravnik; Faustin Kitetele; Annelies Van Rie; Frieda Behets
Journal:  Int J Epidemiol       Date:  2009-05-15       Impact factor: 7.196

7.  Growth, immune and viral responses in HIV infected African children receiving highly active antiretroviral therapy: a prospective cohort study.

Authors:  Philippa M Musoke; Peter Mudiope; Linda N Barlow-Mosha; Patrick Ajuna; Danstan Bagenda; Michael M Mubiru; Thorkild Tylleskar; Mary G Fowler
Journal:  BMC Pediatr       Date:  2010-08-06       Impact factor: 2.125

8.  Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045.

Authors:  Denise L Jacobson; Jane C Lindsey; Catherine M Gordon; Jack Moye; Dana S Hardin; Kathleen Mulligan; Grace M Aldrovandi
Journal:  AIDS       Date:  2010-03-13       Impact factor: 4.177

9.  Prevalence and risk factors of undernutrition among antiretroviral-therapy-naïve subjects aged under 5 years old in Makurdi, Nigeria: a retrospective study.

Authors:  Emmanuel Ademola Anigilaje; Ayodotun Olutola
Journal:  Int J Gen Med       Date:  2015-03-31

10.  Growth patterns among HIV-exposed infants receiving nevirapine prophylaxis in Pune, India.

Authors:  Malathi Ram; Nikhil Gupte; Uma Nayak; Aarti A Kinikar; Mangesh Khandave; Anita V Shankar; Jayagowri Sastry; Robert C Bollinger; Amita Gupta
Journal:  BMC Infect Dis       Date:  2012-10-31       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.